# EDGAR Filing Document

**Accession Number:** 0001454789
**File Stem:** 0001104659-25-076883
**Filing Date:** 2025-8
**Character Count:** 25886
**Document Hash:** c9b60cc2d77c36c1aac11fd768d36322
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-076883.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001104659-25-076883

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250812

**DATE AS OF CHANGE**: 20250812

**EFFECTIVENESS DATE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astria Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001454789
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289533
- **FILM NUMBER:** 251207303

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-349-1971

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATABASIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090127

**As filed with the Securities and Exchange Commission on August 12, 2025**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**Astria Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Delaware** | **26-3687168** |
| (State or Other Jurisdiction of<br> Incorporation or Organization) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| <br> **22 Boston Wharf Road, 10th Floor**<br> **Boston, Massachusetts** | <br>**02210** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Second Amended and Restated 2015 Stock Incentive Plan, as amended**

**2015 Employee Stock Purchase Plan**

**2022 Inducement Stock Incentive Plan, as amended**

(Full Title of the Plan)

**Benjamin Harshbarger**

**Chief Legal Officer<br> 22 Boston Wharf Road, 10th Floor<br> Boston, Massachusetts 02210**

(Name and Address of Agent For Service)

**(617) 349-1971**

(Telephone Number, Including Area Code, of Agent For Service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This Registration Statement on Form S-8, relating to the Second Amended and Restated 2015 Stock Incentive Plan, as amended, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended, of Astria Therapeutics, Inc. (the "Registrant"), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective.

Accordingly, this Registration Statement incorporates by reference the contents of:

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465915060041/a15-17664_1s8.htm) [the Registration Statement on Form S-8, File No. 333-206394, filed with the Securities and Exchange Commission (the "Commission") on August 14, 2015, by the Registrant, relating to the Registrant's Amended and Restated 2008 Equity Incentive Plan, as amended, 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;](https://www.sec.gov/Archives/edgar/data/1454789/000110465915060041/a15-17664_1s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465916105356/a16-6374_1s8.htm) [the Registration Statement on Form S-8, File No. 333-210229, filed with the Commission on March 16, 2016, by the Registrant, relating to the Registrant's 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;](https://www.sec.gov/Archives/edgar/data/1454789/000110465916105356/a16-6374_1s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465917017583/a17-8456_1s8.htm) [the Registration Statement on Form S-8, File No. 333-216793, filed with the Commission on March 17, 2017, by the Registrant, relating to the Registrant's 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;](https://www.sec.gov/Archives/edgar/data/1454789/000110465917017583/a17-8456_1s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465918018272/a18-8369_1s8.htm) [the Registration Statement on Form S-8, File No. 333-223721, filed with the Commission on March 16, 2018, by the Registrant, relating to the Registrant's 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;](https://www.sec.gov/Archives/edgar/data/1454789/000110465918018272/a18-8369_1s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465919007909/a19-4519_1s8.htm) [the Registration Statement on Form S-8, File No. 333-229643, filed with the Commission on February 13, 2019, by the Registrant, relating to the Registrant's Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;](https://www.sec.gov/Archives/edgar/data/1454789/000110465919007909/a19-4519_1s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465920072655/tm2022158d1_s8.htm) [the Registration Statement on Form S-8, File No. 333-239114, filed with the Commission on June 12, 2020, by the Registrant, relating to the Registrant's Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan<u>;</u>](https://www.sec.gov/Archives/edgar/data/1454789/000110465920072655/tm2022158d1_s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465921102145/tm2124476d1_s8.htm) [the Registration Statement on Form S-8, File No. 333-258633, filed with the Commission on August 9, 2021, by the Registrant, relating to the Registrant's Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;](https://www.sec.gov/Archives/edgar/data/1454789/000110465921102145/tm2124476d1_s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465922032509/tm228813d1_s8.htm) [the Registration Statement on Form S-8, File No. 333-263459, filed with the Commission on March 10, 2022, by the Registrant, relating to the Registrant's Amended and Restated 2015 Stock Incentive Plan, 2015 Employee Stock Purchase Plan and 2022 Inducement Stock Incentive Plan;](https://www.sec.gov/Archives/edgar/data/1454789/000110465922032509/tm228813d1_s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465923088387/tm2322563d1_s8.htm) [the Registration Statement on Form S-8, File No. 333-273773, filed with the Commission on August 7, 2023, by the Registrant, relating to the Registrant's Amended and Restated 2015 Stock Incentive Plan, 2015 Employee Stock Purchase Plan and 2022 Inducement Stock Incentive Plan; and](https://www.sec.gov/Archives/edgar/data/1454789/000110465923088387/tm2322563d1_s8.htm)

[·](https://www.sec.gov/Archives/edgar/data/1454789/000110465924088410/tm2421258d1_s8.htm) [the Registration Statement on Form S-8, File No. 333-281491, filed with the Commission on August 12, 2024, by the Registrant, relating to the Registrant's Second Amended and Restated 2015 Stock Incentive Plan, 2015 Employee Stock Purchase Plan and 2022 Inducement Stock Incentive Plan, as amended.](https://www.sec.gov/Archives/edgar/data/1454789/000110465924088410/tm2421258d1_s8.htm)

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8.** **Exhibits.**

The following exhibits are incorporated herein by reference:

**EXHIBIT INDEX**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| <br>**Exhibit<br> Number** | <br>**Description of Exhibit** | **Form** | **File<br> Number** | **Date of Filing** | **Exhibit<br> Number** | <br>**Filed<br> Herewith** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-2.htm) | [Restated Certificate of Incorporation of the Registrant, as amended](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-2.htm) | [8-K](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-2.htm) | [001-37467](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-2.htm) | [June 6, 2023](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-2.htm) | [3.2](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-2.htm) |  |
| [4.2](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-1.htm) | [Amended and Restated By-Laws of the Registrant](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-1.htm) | [8-K](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-1.htm) | [001-37467](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-1.htm) | [June 6, 2023](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1454789/000110465923068331/tm2317750d1_ex3-1.htm) |  |
| [5.1](tm2522936d1_ex5-1.htm) | [Opinion of Sidley Austin LLP, counsel to the Registrant](tm2522936d1_ex5-1.htm) |  |  |  |  | [X](tm2522936d1_ex5-1.htm) |
| [23.1](tm2522936d1_ex5-1.htm) | [Consent of Sidley Austin LLP (included in Exhibit 5.1)](tm2522936d1_ex5-1.htm) |  |  |  |  | [X](tm2522936d1_ex5-1.htm) |
| [23.2](tm2522936d1_ex23-2.htm) | [Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm](tm2522936d1_ex23-2.htm) |  |  |  |  | [X](tm2522936d1_ex23-2.htm) |
| [24.1](#a_001) | [Power of attorney (included on the signature pages of this registration statement)](#a_001) |  |  |  |  | [X](#a_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1454789/000141057825001698/atxs-20250630xex10d1.htm) | [Second Amended and Restated 2015 Stock Incentive Plan, as amended](https://www.sec.gov/Archives/edgar/data/1454789/000141057825001698/atxs-20250630xex10d1.htm) | [10-Q](https://www.sec.gov/Archives/edgar/data/1454789/000141057825001698/atxs-20250630xex10d1.htm) | [001-37467](https://www.sec.gov/Archives/edgar/data/1454789/000141057825001698/atxs-20250630xex10d1.htm) | [August 12, 2025](https://www.sec.gov/Archives/edgar/data/1454789/000141057825001698/atxs-20250630xex10d1.htm) | [10.1](https://www.sec.gov/Archives/edgar/data/1454789/000141057825001698/atxs-20250630xex10d1.htm) |  |
| [99.2](https://www.sec.gov/Archives/edgar/data/1454789/000110465922059405/atxs-20220331xex10d7.htm) | [2015 Employee Stock Purchase Plan](https://www.sec.gov/Archives/edgar/data/1454789/000110465922059405/atxs-20220331xex10d7.htm) | [10-Q](https://www.sec.gov/Archives/edgar/data/1454789/000110465922059405/atxs-20220331xex10d7.htm) | [001-37467](https://www.sec.gov/Archives/edgar/data/1454789/000110465922059405/atxs-20220331xex10d7.htm) | [May 12, 2022](https://www.sec.gov/Archives/edgar/data/1454789/000110465922059405/atxs-20220331xex10d7.htm) | [10.7](https://www.sec.gov/Archives/edgar/data/1454789/000110465922059405/atxs-20220331xex10d7.htm) |  |
| [99.3](https://www.sec.gov/Archives/edgar/data/1454789/000110465924130156/tm2431481d1_ex99-1.htm) | [2022 Inducement Stock Incentive Plan, as amended](https://www.sec.gov/Archives/edgar/data/1454789/000110465924130156/tm2431481d1_ex99-1.htm) | [8-K](https://www.sec.gov/Archives/edgar/data/1454789/000110465924130156/tm2431481d1_ex99-1.htm) | [001-37467](https://www.sec.gov/Archives/edgar/data/1454789/000110465924130156/tm2431481d1_ex99-1.htm) | [December 19, 2024](https://www.sec.gov/Archives/edgar/data/1454789/000110465924130156/tm2431481d1_ex99-1.htm) | [99.1](https://www.sec.gov/Archives/edgar/data/1454789/000110465924130156/tm2431481d1_ex99-1.htm) |  |
| [107](tm2522936d1_ex-filingfees.htm) | [Filing Fee Table](tm2522936d1_ex-filingfees.htm) |  |  |  |  | [X](tm2522936d1_ex-filingfees.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Boston, Commonwealth of Massachusetts, on this 12th day of August, 2025.

---

| | |
|:---|:---|
| ASTRIA THERAPEUTICS, INC. | ASTRIA THERAPEUTICS, INC. |
| By: | /s/ Jill C. Milne |
|  | Jill C. Milne |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES**

We, the undersigned officers and directors of Astria Therapeutics, Inc., hereby severally constitute and appoint Jill C. Milne, Benjamin Harshbarger and Noah Clauser, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Astria Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jill C. Milne | President and Chief Executive Officer and Director<br> (*Principal Executive Officer*) | August 12, 2025 |
| Jill C. Milne | President and Chief Executive Officer and Director<br> (*Principal Executive Officer*) |  |
| /s/ Noah Clauser | Chief Financial Officer and Treasurer | August 12, 2025 |
| Noah Clauser | (*Principal Financial Officer and Principal Accounting Officer*) |  |
| /s/ Kenneth Bate | Chairman of the Board of Directors | August 12, 2025 |
| Kenneth Bate |  |  |
| /s/ Sunil Agarwal | Director | August 12, 2025 |
| Sunil Agarwal |  |  |
| /s/ Joanne Beck | Director | August 12, 2025 |
| Joanne Beck |  |  |
| /s/ Frederick P. Callori | Director | August 12, 2025 |
| Frederick P. Callori |  |  |
| /s/ Hugh Cole | Director | August 12, 2025 |
| Hugh Cole |  |  |
| /s/ Michael Kishbauch | Director | August 12, 2025 |
| Michael Kishbauch |  |  |
| /s/ Gregg Lapointe | Director | August 12, 2025 |
| Gregg Lapointe |  |  |
| /s/ Jonathan Violin | Director | August 12, 2025 |
| Jonathan Violin |  |  |

---

## Exhibit 5.1

**EXHIBIT 5.1**

---

| | |
|:---|:---|
| <br> ![](tm2522936d1_ex5-1img001.jpg) | SIDLEY AUSTIN LLP |
| <br> ![](tm2522936d1_ex5-1img001.jpg) | 60 STATE STREET |
| <br> ![](tm2522936d1_ex5-1img001.jpg) | BOSTON, MA 02109 |
| <br> ![](tm2522936d1_ex5-1img001.jpg) | +1 617 223 0300 |
| <br> ![](tm2522936d1_ex5-1img001.jpg) | +1 617 223 0301 FAX |
| <br> ![](tm2522936d1_ex5-1img001.jpg) |  |
| <br> ![](tm2522936d1_ex5-1img001.jpg) | AMERICA · ASIA PACIFIC · EUROPE |

---

August 12, 2025

Astria Therapeutics, Inc.

22 Boston Wharf Road, 10th Floor

Boston, MA 02210

---

| | |
|:---|:---|
| Re: | <u>6,606,078 Shares of Common Stock, $0.001 par value per share</u> |

---

Ladies and Gentlemen:

We refer to the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") being filed by Astria Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), relating to the registration of an aggregate of 6,606,078 shares of Common Stock, $0.001 par value per share (the "<u>Registered Shares</u>"), of the Company, of which 5,500,000 shares may be issued under the Second Amended and Restated 2015 Stock Incentive Plan, as amended (the "<u>Stock Incentive Plan</u>"), 6,078 shares may be issued under the 2015 Employee Stock Purchase Plan (the "<u>ESPP</u>"), and 1,100,000 shares may be issued under the 2022 Inducement Stock Incentive Plan, as amended (the "<u>Inducement Plan</u>" and together with the Stock Incentive Plan and the ESPP, the "<u>Plans</u>").

This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

We have examined the Registration Statement, the Company's certificate of incorporation, the Plan, the resolutions adopted by the board of directors of the Company relating to the Registration Statement and the Plans, and the proposals adopted by the stockholders of the Company relating to the Stock Incentive Plan and the ESPP. We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company.

Based on the foregoing, we are of the opinion that each Registered Share that is newly issued pursuant to the Plans will be validly issued, fully paid and non-assessable when: (i) the Registration Statement, as finally amended, shall have become effective under the Securities Act; (ii) such Registered Share shall have been duly issued and delivered in accordance with the Plans; and (iii) certificates representing such Registered Share shall have been duly executed, countersigned and registered and duly delivered to the person entitled thereto against payment of the agreed consideration therefor in an amount not less than the par value thereof or, if any Registered Share is to be issued in uncertificated form, the Company's books shall reflect the issuance of such Registered Share to the person entitled thereto against payment of the agreed consideration therefor in an amount not less than the par value thereof, all in accordance with the Plans.

Sidley Austin LLP is a limited liability partnership practicing in affiliation with other Sidley Austin partnerships.

![](tm2522936d1_ex5-1img001.jpg)

Astria Therapeutics, Inc.

August 12, 2025

This opinion letter is limited to the General Corporation Law of the State of Delaware. We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.

We hereby consent to the filing of this opinion letter as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

---

| |
|:---|
| Very truly yours, |
| /s/ Sidley Austin LLP |
| SIDLEY AUSTIN LLP |

---

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Second Amended and Restated 2015 Stock Incentive Plan, as amended, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended, of Astria Therapeutics, Inc. of our report dated March 11, 2025, with respect to the consolidated financial statements of Astria Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

August 12, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Astria Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.001 par value per share | Other | 6606078 | $6.44 | $42543142.32 | 0.0001531 | $6513.36 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $42543142.32  |  | $6513.36  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $6513.36  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> 1(a) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. 1(b) Consists of (i) 5,500,000 shares issuable under the Second Amended and Restated 2015 Stock Incentive Plan, as amended, (ii) 6,078 shares issuable under the 2015 Employee Stock Purchase Plan, and (iii) 1,100,000 shares issuable under the 2022 Inducement Stock Incentive Plan, as amended. 1(c) The proposed maximum offering price per share of $6.44is estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act and is based upon the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Market on August 8, 2025.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---